Clinical Trial Update: Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating BCMA CAR-T cell therapy in patients with BCMA-positive relapsed or refractory multiple myeloma has completed with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T cells (BCMA-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2022-08-05